Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 0 trial completion68d agoKey Projects of Science and Technology Department of Sichuan Province — dantrolene (Phase 0 Trial Completion)dantrolene

Therapy area: Cardiovascular. Indication: Ischemia, Myocardial Ischemia, Ventricular Arrhythmia

full page →dantrolene →source: globaldata

Apr 30, 2026phase 0 trial completion68d agoInner Mongolia Aerospace Hospital — (bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) (Phase 0 Trial Completion)(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12)

Therapy area: Cardiovascular, Gastrointestinal. Indication: Atherosclerosis, Irritable Bowel Syndrome

full page →(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) →source: globaldata

Apr 30, 2026phase 1 completion68d agoDongguan Traditional Chinese Medicine Hospital — undisclosed traditional Chinese medicine (Phase I Trial Completion)undisclosed traditional Chinese medicine

Therapy area: Immunology, Musculoskeletal Disorders. Indication: Osteoporosis, Rheumatoid Arthritis, Sarcopenia

full page →undisclosed traditional Chinese medicine →source: globaldata

Apr 30, 2026phase 1 completion68d agoJiangxi Jemincare Group Co Ltd — JMKX-003142 (Phase I Trial Completion)JMKX-003142

Therapy area: Cardiovascular, Genetic Disorders. Indication: Edema, Polycystic Kidney Disease

full page →JMKX-003142 →source: globaldata

Apr 30, 2026phase 1 completion68d agoCheng Du Sheng Nuo Biotec Co Ltd — CIGB-814 (Phase I Trial Completion)CIGB-814

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →CIGB-814 →source: globaldata

Apr 30, 2026phase 1 completion68d agoEcolab Inc — (acetaminophen + ibuprofen) (Phase I Trial Completion)(acetaminophen + ibuprofen)

Therapy area: Central Nervous System, Ear Nose Throat Disorders, Hormonal Disorders, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Ankylosing Spondylitis (Bekhterev's Disease), Dental Pain (Toothache/Tooth Pain), Fever, Fibromyalgia (Fibromyalgia Syndrome), Gouty Arthritis (Gout), Hyperthyroidism, Laryngitis, Low Back Pain, Mixed Pain (Nociceptive Pain/Neuropathic Pain), Musculoskeletal Inflammation, Musculoskeletal Pain, Myalgia (Muscle Pain), Neuropathic Pa

full page →(acetaminophen + ibuprofen) →source: globaldata

Apr 30, 2026phase 1 completion68d agoBeijing Minhai Biotechnology Co Ltd — pneumococcal (20-valent) vaccine (Phase I Trial Completion)pneumococcal (20-valent) vaccine

Therapy area: Respiratory. Indication: Streptococcal Pneumonia

full page →pneumococcal (20-valent) vaccine →source: globaldata

Apr 30, 2026phase 1 completion68d agoJiangsu Postgraduate Research and Practice Innovation Program — acetaminophen (Phase I Trial Completion)acetaminophen ER

Therapy area: Cardiovascular. Indication: Patent Ductus Arteriosus

full page →acetaminophen ER →source: globaldata

Apr 30, 2026phase 1 completion68d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

Therapy area: Immunology. Indication: Inflammation

full page →FT-2109 →source: globaldata

Apr 30, 2026phase 1 completion68d agoPhrae Hospital — bupivacaine (Phase I Trial Completion)bupivacaine

Therapy area: Cardiovascular, Central Nervous System, Gastrointestinal. Indication: Hypotension, Post Operative Nausea And Vomiting, Post-Operative Pain

full page →bupivacaine →source: globaldata

Apr 30, 2026phase 1 completion68d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

Therapy area: Immunology. Indication: Inflammation

full page →FT-2109 →source: globaldata

Apr 30, 2026phase 1 completion68d agoBarts Charity — undisclosed Covid-19 vaccine (Phase I Trial Completion)undisclosed Covid-19 vaccine

Therapy area: Cardiovascular. Indication: Cardiovascular Disease, Endothelial Dysfunction

full page →undisclosed Covid-19 vaccine →source: globaldata

Apr 30, 2026phase 1 completion68d agoInsignis Therapeutics Inc — HLK-0006 (Phase I Trial Completion)HLK-0006

Therapy area: Immunology. Indication: Anaphylaxis, Food Allergy, Peanut Allergy

full page →HLK-0006 →source: globaldata

Apr 30, 2026phase 1 initiation68d agoEgyptian International Pharmaceuticals Industries Co SAE — enoxaparin sodium biosimilar (Phase I Trial Initiation)enoxaparin sodium biosimilar

Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Congestive Heart Failure (Heart Failure), Deep Vein Thrombosis (DVT), Myocardial Infarction, Pulmonary Embolism, Thromboembolic Disease, Thromboembolism, Thrombosis, Unstable Angina, Venous (Vein) Thrombosis, Venous Thromboembolism

full page →enoxaparin sodium biosimilar →source: globaldata

Apr 30, 2026phase 1 initiation68d agoFirst Affiliated Hospital of Bengbu Medical University — Loberamisal (Phase I Trial Initiation)Loberamisal

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke

full page →Loberamisal →source: globaldata

Apr 30, 2026phase 1 initiation68d agoBio-Innova Co Ltd — dapagliflozin (Phase I Trial Initiation)DAPAGLIFLOZIN

Therapy area: Cardiovascular, Genito Urinary System, Metabolic Disorders. Indication: Cardiovascular Risk Factors, Diabetic Nephropathy, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes

full page →DAPAGLIFLOZIN →source: globaldata

Apr 30, 2026phase 1 initiation68d agoNanjing IASO Biotherapeutics Co Ltd — IASO-782 (Phase I Trial Initiation)IASO-782

Therapy area: Immunology. Indication: Systemic Lupus Erythematosus

full page →IASO-782 →source: globaldata

Apr 30, 2026phase 1 2 completion68d agoDuke University — deferiprone (Phase I/II Trial Completion)deferiprone

Therapy area: Cardiovascular, Central Nervous System. Indication: Cerebral Aneurysms, Dementia, Stroke, Subarachnoid Hemorrhage

full page →deferiprone →source: globaldata

Apr 30, 2026phase 1 2 completion68d agoImplicit Bioscience Ltd — Atibuclimab (Phase I/II Trial Completion)Atibuclimab

Therapy area: Cardiovascular. Indication: Acute Decompensated Heart Failure, Congestive Heart Failure (Heart Failure)

full page →Atibuclimab →source: globaldata

Apr 30, 2026phase 1 2 completion68d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

full page →M-701 →source: globaldata

Apr 30, 2026phase 2 completion68d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

full page →UA-021 →source: globaldata

Apr 30, 2026phase 2 completion68d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →telitacicept →source: globaldata

Apr 30, 2026phase 2 completion68d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

full page →autologous regulatory T cells →source: globaldata

Apr 30, 2026phase 2 completion68d agoBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)dupilumab

Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis

full page →dupilumab →source: globaldata

Apr 30, 2026phase 2 completion68d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

full page →tulisokibart →source: globaldata

Apr 30, 2026phase 2 completion68d agoGerman Sport University Cologne — polyphenol-rich cocoa extract (Phase II Trial Completion)polyphenol-rich cocoa extract

Therapy area: Cardiovascular. Indication: Idiopathic (Essential) Hypertension

full page →polyphenol-rich cocoa extract →source: globaldata

Apr 30, 2026phase 2 completion68d agoMedanta - The Medicity — centhaquine citrate (Phase II Trial Completion)centhaquine citrate

Therapy area: Cardiovascular, Other Diseases. Indication: Hemorrhagic Shock, Injury, Trauma

full page →centhaquine citrate →source: globaldata

Apr 30, 2026phase 2 completion68d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

full page →ozonated oil →source: globaldata

Apr 30, 2026phase 2 completion68d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — lenvatinib (Phase II Trial Completion)lenvatinib

Therapy area: Cardiovascular, Oncology. Indication: Hepatocellular Carcinoma, Thrombosis, Venous (Vein) Thrombosis

full page →lenvatinib →source: globaldata

Apr 30, 2026phase 2 completion68d agoMedical University of Gdansk — apixaban (Phase II Trial Completion)apixaban ODT

Therapy area: Cardiovascular, Oncology. Indication: Diffuse Large B-Cell Lymphoma, Hematological Tumor, Leukemia, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Pulmonary Embolism, Thromboembolic Disease, Venous Thromboembolism

full page →apixaban ODT →source: globaldata

Apr 30, 2026phase 2 completion68d agoNeurodawn Pharmaceutical Co Ltd — Loberamisal (Phase II Trial Completion)Loberamisal

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Cerebral Infarction (Brain Infarction)

full page →Loberamisal →source: globaldata

Apr 30, 2026phase 2 completion68d agoSohag University — ephedrine (Phase II Trial Completion)ephedrine

Therapy area: Cardiovascular. Indication: Hypotension

full page →ephedrine →source: globaldata

Apr 30, 2026phase 2 completion68d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

full page →metformin hydrochloride ER →source: globaldata

Apr 30, 2026phase 2 completion68d agoAstraZeneca Plc — tozorakimab (Phase II Trial Completion)tozorakimab

Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

full page →tozorakimab →source: globaldata

Apr 30, 2026phase 2 completion68d agoCurtin University — influenza vaccine (Phase II Trial Completion)influenza vaccine

Therapy area: Cardiovascular. Indication: Myocardial Infarction

full page →influenza vaccine →source: globaldata

Apr 30, 2026phase 2 completion68d agoRenji Hospital — norepinephrine (Phase II Trial Completion)norepinephrine

Therapy area: Genito Urinary System, Immunology. Indication: Delayed Graft Function (DGF), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

full page →norepinephrine →source: globaldata

Apr 30, 2026phase 2 completion68d agoDutch Heart Foundation — ghrelin (Phase II Trial Completion)ghrelin

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Ischemic Stroke

full page →ghrelin →source: globaldata

Apr 30, 2026phase 2 completion68d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

Therapy area: Immunology. Indication: Inflammation

full page →SSJG-009 →source: globaldata

Apr 30, 2026phase 2 completion68d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

Therapy area: Respiratory. Indication: Cough

full page →LIDOCAINE →source: globaldata

← prev

page 2 of 2

Week of Apr 27, 2026